Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for 10x Genomics despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - 10x Genomics is expected to report a quarterly loss of $0.27 per share, reflecting a year-over-year change of +10% [3]. - Revenue is projected to be $142.39 million, down 6.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for 10x Genomics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +11.39% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 [10]. - 10x Genomics currently holds a Zacks Rank of 1, indicating strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, 10x Genomics was expected to post a loss of $0.35 per share but instead reported earnings of $0.28, resulting in a surprise of +180% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical Info Systems industry, Nyxoah SA is expected to report a loss of $0.61 per share, indicating a year-over-year change of -10.9% [18]. - Nyxoah's revenue is expected to be $1.95 million, up 40.3% from the previous year [18]. - Despite a higher Most Accurate Estimate leading to an Earnings ESP of +19.67%, Nyxoah's Zacks Rank of 4 (Sell) complicates predictions for an earnings beat [19].

Core Insights - 10x Genomics has launched a next-generation high-performance Flex assay that features automation-compatible plate-based multiplexing, enabling cost-effective and scalable single-cell analysis for a variety of research applications [1][2][3] Group 1: Product Features - The new Flex assay allows researchers to profile up to 384 samples and 100 million cells per week using a 96-well plate format, integrating seamlessly with automated cell partitioning for reliable results [2] - Built on proven Flex chemistry, the assay offers exceptional sensitivity and sequencing efficiency, supporting modular usage and reducing reagent waste, thus delivering more data at a lower cost [2][3] - The assay enables the profiling of millions of cells at a fraction of the cost compared to traditional methods, significantly enhancing the ability to explore functional immune responses [4] Group 2: Market Impact - The advancements in scalability and ease of use are expected to unlock more research opportunities, allowing for more samples, conditions, and insights at reduced costs [3] - The new Flex assay is positioned as a transformative tool for large-scale foundational and translational studies, as well as routine single-cell applications [3] - Early access customers have already begun utilizing the new Flex assay across various discovery and translational research programs, indicating strong market interest [3][4] Group 3: Company Overview - 10x Genomics is a life science technology company focused on products that accelerate biological research and advance human health, with solutions that include instruments, consumables, and software for single-cell and spatial biology [5] - The company's products have contributed to breakthroughs in various fields, including oncology, immunology, and neuroscience, enhancing the understanding of health and disease [5]

Company Overview - 10x Genomics (TXG) shares increased by 11.1% to $13.14 in the last trading session, following a period of 9.3% loss over the past four weeks, indicating a significant rebound in investor sentiment [1][2] Recent Developments - The stock's price surge is attributed to a collaboration with Anthropic, which aims to integrate 10x's advanced analysis tools into Claude for Life Sciences, enhancing accessibility to single-cell and spatial biology technologies through natural language [2] Financial Expectations - 10x Genomics is projected to report a quarterly loss of $0.27 per share, reflecting a year-over-year increase of 10%, while revenues are expected to be $142.39 million, down 6.1% from the previous year [3] - The consensus EPS estimate has been revised 3.6% lower over the last 30 days, suggesting a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - 10x Genomics is part of the Zacks Medical Info Systems industry, which includes other companies like Omnicell (OMCL), whose stock closed 1% higher at $30.2, but has seen a return of -4.6% over the past month [4] - Omnicell's consensus EPS estimate has increased by 8.2% over the past month to $0.36, although this represents a year-over-year decline of 35.7% [5]

Core Insights - 10x Genomics and Anthropic have announced a collaboration to integrate 10x's single cell and spatial biology analysis tools into Anthropic's Claude for Life Sciences, enabling researchers to interact with complex datasets using natural language [1][2][3] Company Overview - 10x Genomics is a life science technology company focused on products that enhance the understanding of biological systems, particularly in single cell and spatial biology, which are crucial for advancements in fields like oncology and immunology [4] - Anthropic is an AI research and development company known for creating reliable and interpretable AI systems, with its flagship product being Claude, a large language model designed for business applications [5] Collaboration Details - The collaboration aims to lower the technical barriers traditionally associated with accessing 10x's analysis capabilities, allowing researchers to perform tasks such as clustering and data interpretation through a conversational interface [2][3] - This partnership is positioned as a significant step towards making complex biological analysis more intuitive and accessible, fostering a synergy between human expertise and AI capabilities [3]

Core Viewpoint - 10x Genomics (TXG) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Investor Sentiment - The upgrade for 10x Genomics suggests an improvement in the company's underlying business, which should encourage investors to drive the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for 10x Genomics has increased by 25.5%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of 10x Genomics to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Core Insights - 10x Genomics, Inc. will report its financial results for Q3 2025 on November 6, 2025, after market close [1] - A public conference call and live webcast will be held to discuss the results, business developments, and outlook [1] - The webcast will be available for replay for at least 45 days after the event [2] Company Overview - 10x Genomics is a life science technology company focused on products that enhance the understanding of biology and improve human health [3] - The company offers integrated research solutions, including instruments, consumables, and software for single cell and spatial biology [3] - Its products contribute to advancements in various fields such as oncology, immunology, and neuroscience, facilitating significant discoveries in health and disease [3]

Group 1 - The article discusses the initial coverage of 10x Genomics (NASDAQ: TXG) with a pessimistic outlook due to expected persistent losses through at least 2028 despite a strong balance sheet [1] - The analyst highlights a focus on finding underappreciated companies that can return value to investors, indicating a contrarian investment philosophy [1] Group 2 - There are no stock, option, or similar derivative positions held by the analyst in any mentioned companies, nor plans to initiate such positions within the next 72 hours [2] - The article expresses the author's own opinions without receiving compensation from any company mentioned [2]

Summary of Analyst Ratings Changes Core Viewpoint - Top Wall Street analysts have revised their outlook on several companies, providing new ratings and price targets for their stocks [1]. Company-Specific Summaries - **Eaton Corporation plc (ETN)**: Daiwa Capital analyst Jairam Nathan initiated coverage with an Outperform rating and a price target of $390, while shares closed at $362.25 [6]. - **Synaptics Incorporated (SYNA)**: Deutsche Bank analyst Ross Seymore initiated coverage with a Buy rating and a price target of $85, with shares closing at $69.10 [6]. - **Celsius Holdings, Inc. (CELH)**: Goldman Sachs analyst Bonnie Herzog initiated coverage with a Buy rating and a price target of $72, while shares closed at $56.22 [6]. - **Solventum Corporation (SOLV)**: Jefferies analyst Michael Toomey initiated coverage with a Hold rating and a price target of $80, with shares closing at $71.22 [6]. - **10x Genomics, Inc. (TXG)**: Piper Sandler analyst David Westenberg initiated coverage with a Neutral rating and a price target of $15, while shares closed at $12.59 [6].

Core Insights - The past nine months have been eventful for 10x Genomics, marked by significant changes in the macro environment and various policy headwinds impacting end markets [1] Company Performance - The company started the year with strong momentum, but faced numerous challenges throughout the year [1] - The CEO expressed pride in the team's execution despite the ongoing difficulties and challenges encountered [1]

Core Insights - The past nine months have been eventful for 10x Genomics, marked by significant changes in the macro environment and various policy headwinds impacting end markets [1] Company Performance - The company started the year with strong momentum, but faced numerous challenges throughout the year [1] - The CEO expressed pride in the team's execution despite the ongoing difficulties and challenges encountered [1]